Table 2. NGS of EGFR axons 7-13, KRAS exons 2/3/4 and NRAS exons 2/3/4 in pre- and post-treatment samples from the "tumor tissue" patient cohort.^*.

		time point 1				time point 2
pat. #	category	sample 1	EGFR (ex.7-13)	KRAS (ex. 2/3/4)	NRAS (ex. 2/3/4)	sample 2	EGFR (ex. 7-13)	KRAS (ex. 2/3/4)	NRAS (ex. 2/3/4)
1	panitumumab group	primary tumor	wt	wt	wt	liver metastasis	wt	wt	wt
2		primary tumor	wt	wt	wt	primary tumor/LN1/LN2	G465R (3.5%)/G465R (6.8%)/wt	wt/wt/wt	wt/wt/wt
3		primary tumor	wt	wt	wt	-	-	-	-
4		liver metastasis	wt	wt	wt	-	-	-	-
5		-	-	-	-	lung metastasis	wt	wt	wt
6		liver metastasis	wt	wt	wt	-	-	-	-
7		liver metastasis	wt	wt	cod. 61 (Q-> K. 22.2%)	-	-	-	-
8		primary tumor	wt	wt	wt	-	-	-	-
9	cetuximab group	-	-	-	-	liver metastasis	wt	wt	wt
10		primary tumor	wt	wt	wt	-	-	-	-
11		-	-	-	-	primary tumor	wt	wt	wt
12		liver metastasis	wt	wt	wt	-	-	-	-
13		liver metastasis	wt	wt	wt	liver metastasis	wt	wt	wt
14		-	-	-	-	abdominal metastasis	wt	wt	wt
15		LN metastasis	wt	wt	wt	-	-	-	-
16		primary tumor	wt	wt	wt	-	-	-	-
17	control group (w/o EGFR-targeted therapy)	primary tumor	wt	cod. 12 (G -> V. 20.4%)	wt	liver metastasis	wt	wt	wt
18		-	-	-	-	liver metastasis	wt	wt	wt
19		-	-	-	-	liver metastasis	wt	cod. 12 (G->V, 38.7%)	wt
20		liver metastasis	wt	cod. 12 (G->D, 40.2%)	wt	-	-	-	-
21		primary tumor	wt	wt	wt	liver metastasis	wt	wt	wt

^*time point 1 = pre-treatment (rfering to panitumumab/cetuximab/control treatment), time point 2 = post-treatment (refering to panitumumab/cetuximab/control treatment); wt = wild type, LN = lymph node, ex. = exon, cod.= codon, % = percentage of reads